Biotechnology - Alnylam Pharmaceuticals

Filter

Current filters:

Alnylam Pharmaceuticals

Popular Filters

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics

13-01-2014

US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

Ph I cholesterol lowerer offers new hope for patients resistant to statins

04-10-2013

A study published in The Lancet found that participants in a Phase I clinical trial saw their level of…

ALN-PCSAlnylam PharmaceuticalsBiotechnologyCardio-vascularResearch

The Medicines Company gets rights to Alnylam's PCSK9 inhibitors program for cholesterol

05-02-2013

USA-based The Medicines Company (Nasdaq: MDCO) has formed an exclusive global alliance with RNAi therapeutics…

Alnylam PharmaceuticalsAngiomaxBiotechnologyCardio-vascularLicensingPharmaceuticalThe Medicines Company

Alnylam and Tekmira restructure relationship and settle all litigation in $65 million deal

14-11-2012

USA-based Alnylam Pharmaceuticals (Nasdaq: ALNY) says it has restructured its relationship with Canadian…

Alnylam PharmaceuticalsBiotechnologyFinancialLegalLicensingPharmaceuticalTekmira Pharmaceuticals

Alnylam gets upfront $22.5 million in RNAi link with Genzyme

23-10-2012

French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

Early-stage cholesterol drug offers new hope for patients resistant to statins

03-10-2012

A study published in The Lancet found that participants in a Phase I clinical trial saw their level of…

ALN-PCSAlnylam PharmaceuticalsBiotechnologyCardio-vascularResearch

Silencing investor concerns? Alnylam achieves RNAi milestone

02-08-2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines

Alnylam and Ascletis collaborate to develop ALN-VSP for liver cancers in China

15-07-2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) and Ascletis Pharmaceuticals,…

ALN-VSPAlnylam PharmaceuticalsAscletis PharmaceuticalsAsia-PacificBiotechnologyLicensingOncology

Alnylam's RSV drug candidate misses primary endpoint in Ph IIb

31-05-2012

Leading USA-based RNAi therapeutics firm Alnylam Pharmaceuticals (Nasdaq: ALNY) yesterday announced disappointing…

Alnylam PharmaceuticalsBiotechnologyResearchRespiratory and Pulmonary

Alnylam looks to save $20 million via restructuring

22-01-2012

USA-based RNAi therapeutics specialist Alnylam Pharmaceuticals (Nasdaq: ALNY) said last week that it…

Alnylam PharmaceuticalsBiotechnologyFinancialManagement

Parexel

Parexel

Back to top